Drug Profile

CP 2090

Alternative Names: CP-2090

Latest Information Update: 28 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ube Industries
Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Small molecules
Mechanism of Action Lysophosphatidic acid receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

No development reported Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis

28 Apr 2022 No recent reports of development identified for research development in Idiopathic-pulmonary-fibrosis in Japan
28 Apr 2022 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in Japan
29 Mar 2018 Curadim Pharma acquires rights from Ube Industries to develop, manufacture and market CP 2090 formulations worldwide

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com